NL 103
Alternative Names: NL-103Latest Information Update: 30 Jan 2023
Price :
$50 *
At a glance
- Originator Neurovation Labs
- Class Anxiolytics; Small molecules
- Mechanism of Action Ionotropic glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Post-traumatic stress disorders
Most Recent Events
- 15 Dec 2022 Early research in Post-traumatic stress disorders in USA (PO) Before December 2022 (Neurovation Labs pipeline, December 2022)
- 13 Sep 2022 Neurovation Labs has patent protection for compositions and methods for diagnosing and treatment of Post-traumatic stress disorders and Neurological disorders in USA
- 21 Jun 2022 Neurovation Labs receives SBIR grant from Department of defense for development of candidates in Post-traumatic stress disorder